PT  - JOURNAL ARTICLE
AU  - Géraldine Lescaille
AU  - Amélie E. Coudert
AU  - Vanessa Baaroun
AU  - Marie-José Javelot
AU  - Martine Cohen-Solal
AU  - Ariane Berdal
AU  - Patrick Goudot
AU  - Jean Azérad
AU  - Blandine Ruhin
AU  - Vianney Descroix
TI  - Osteonecrosis of the Jaw and Nonmalignant Disease: Is There an Association with Rheumatoid Arthritis?
AID  - 10.3899/jrheum.120810
DP  - 2013 Jun 01
TA  - The Journal of Rheumatology
PG  - 781--786
VI  - 40
IP  - 6
4099  - http://www.jrheum.org/content/40/6/781.short
4100  - http://www.jrheum.org/content/40/6/781.full
SO  - J Rheumatol2013 Jun 01; 40
AB  - Objective. To review cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) occurring in association with benign disease and to describe and compare the clinical course and outcome for patients with BRONJ and rheumatoid arthritis (RA) or osteoporosis. Methods. We retrospectively reviewed observations of all patients referred for treatment and followup for BRONJ from January 2007 to December 2011. Only patients with malignant disease were excluded. Demographic data, medical history, maxillofacial findings, BRONJ treatment, and followup were reviewed for each case. Results. Over a 5-year period, we diagnosed 112 patients with BRONJ. Among these patients, 15 received bisphosphonate (BP) treatment for nonmalignant disease (mean age 65.7 ± 19.8 yrs, 80% women). Patients received BP for a variety of reasons: 8 (53%) to prevent osteoporosis in association with underlying RA; 6 (40%) to prevent idiopathic osteoporosis; and 1 (7%) to treat ankle algodystrophy. The mean oral BP exposure period was 48.4 months (median 36 mo). In 13 cases (86.6%), BRONJ was diagnosed following dental extraction. Of the 8 patients with RA, 5 (62.5%) were taking prednisone at the time of the discovery of BRONJ. Major surgery, sequestrectomy, or alveolectomy was performed in 9 patients (60%), all of whom healed within 3 to 36 months (mean 11.5 mo). Comparative analysis of all the variables showed no statistically significant differences between patients with RA and others. Conclusion. ONJ is a rare adverse effect of BP therapy, especially when administered orally. Within the limits of our study, we were unable to demonstrate a difference in BRONJ disease spectrum, clinical course, or outcome between patients with and those without RA.